Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
Org chart
Collapse
Teams
Offices
This company has no offices yet
Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
This company has no offices yet
